0000904454-18-000329.txt : 20180502 0000904454-18-000329.hdr.sgml : 20180502 20180502162901 ACCESSION NUMBER: 0000904454-18-000329 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180430 FILED AS OF DATE: 20180502 DATE AS OF CHANGE: 20180502 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Hoffmann Rolf K CENTRAL INDEX KEY: 0001737142 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36066 FILM NUMBER: 18800042 MAIL ADDRESS: STREET 1: LORBEERWEG 7 CITY: WEGGIS STATE: V8 ZIP: CH-6353 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Paratek Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001178711 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330960223 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 75 PARK PLAZA STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 BUSINESS PHONE: (617) 807-6600 MAIL ADDRESS: STREET 1: 75 PARK PLAZA STREET 2: 4TH FLOOR CITY: BOSTON STATE: MA ZIP: 02116 FORMER COMPANY: FORMER CONFORMED NAME: Transcept Pharmaceuticals Inc DATE OF NAME CHANGE: 20090130 FORMER COMPANY: FORMER CONFORMED NAME: NOVACEA INC DATE OF NAME CHANGE: 20020724 4 1 edgar.xml PRIMARY DOCUMENT X0306 4 2018-04-30 0001178711 Paratek Pharmaceuticals, Inc. PRTK 0001737142 Hoffmann Rolf K C/O PARATEK PHARMACEUTICALS, INC. 75 PARK PLAZA, 4TH FLOOR BOSTON MA 02116 1 0 0 0 Common Stock 2018-04-30 4 A 0 15000 0 A 18500 D Stock Option (right to buy) 10.70 2018-04-30 4 A 0 10000 0 A 2028-04-30 Common Stock 10000 10000 D Represents restricted stock units granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan, pursuant to the Paratek Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, effective January 1, 2018. Each restricted stock unit represents the contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest as to 1/3 of the shares subject to the restricted stock units on April 30, 2019, and on the same calendar date of each successive year thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. The exercise price is equal to the closing sales price per share of Common Stock as reported on The Nasdaq Global Market on the date of grant. The stock option was granted to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan, pursuant to the Paratek Pharmaceuticals, Inc. Non-Employee Director Compensation Policy, effective January 1, 2018. The stock option shall vest as to 1/36 of the shares on May 31, 2018, and on the last day of each successive month thereafter until fully vested, subject to the Reporting Person's continued service with the Issuer through each vesting date. /s/ William M. Haskel, Attorney-in-Fact for Rolf K. Hoffmann 2018-05-02